Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11496238 | 0.86 | L3MBTL1 (0.41) | CTSDKMT2ATDP1L3MBTL1ALDH1A1 | |
| SCHEMBL3421177 | 0.84 | ALOX5 (0.38) | HTTGAAMEN1KMT2AALDH1A1 | |
| SCHEMBL3424676 | 0.84 | HDAC3 (0.41) | HTTGAAALDH1A1HDAC3HDAC4 | |
| SCHEMBL11500988 | 0.83 | L3MBTL1 (0.39) | GAACTSDMEN1KMT2ATDP1 | |
| SCHEMBL3421533 | 0.82 | HDAC4 (0.47) | HDAC4HDAC7HDAC5EPHX1 | |
| SCHEMBL3423171 | 0.82 | ADRA2A (0.40) | CYP2D6EPHX1 | |
| SCHEMBL3431710 | 0.82 | PARP1 (0.38) | TDP1PKM | |
| SCHEMBL1023690 | 0.76 | — | — | |
| SCHEMBL29270200 | 0.75 | HTT (0.43) | HTTGAACTSDMEN1KMT2A | |
| SCHEMBL741751 | 0.75 | MEN1 (0.58) | CTSDMEN1KMT2ATDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116003323-B | Fluorine-containing pyrazole phenylacetamide derivative and application thereof | 西北农林科技大学 | 2023-12-08 | — | — | CN | claimed |
| CN-116003323-A | Fluorine-containing pyrazole phenylacetamide derivative and application thereof | 西北农林科技大学 | 2023-04-25 | — | — | CN | claimed |
| JP-4555547-B2 | — | — | 2010-10-06 | — | — | JP | claimed |
| JP-2004505977-A | — | — | 2004-02-26 | — | — | JP | claimed |
| EP-1320531-A2 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | Pharmacia Italia S.p.A. (IT) | 2003-06-25 | — | — | EP | claimed |
| WO-2002012242-A2 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PHARMACIA ITALIA S.P.A. (IT) | 2002-02-14 | — | — | WO | claimed |
| CN-116003323-B | Fluorine-containing pyrazole phenylacetamide derivative and application thereof | 西北农林科技大学 | 2023-12-08 | — | — | CN | disclosed |
| CN-116003323-B | Fluorine-containing pyrazole phenylacetamide derivative and application thereof | 西北农林科技大学 | 2023-12-08 | — | — | CN | disclosed |
| CN-116003323-B | Fluorine-containing pyrazole phenylacetamide derivative and application thereof | 西北农林科技大学 | 2023-12-08 | — | — | CN | disclosed |
| CN-116003323-A | Fluorine-containing pyrazole phenylacetamide derivative and application thereof | 西北农林科技大学 | 2023-04-25 | — | — | CN | disclosed |
| CN-116003323-A | Fluorine-containing pyrazole phenylacetamide derivative and application thereof | 西北农林科技大学 | 2023-04-25 | — | — | CN | disclosed |
| CN-116003323-A | Fluorine-containing pyrazole phenylacetamide derivative and application thereof | 西北农林科技大学 | 2023-04-25 | — | — | CN | disclosed |
| US-11213520-B2 | Phenylpyrazolylacetamide compounds and derivatives as CDK8/CDK19 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-01-04 | — | — | US | disclosed |
| WO-2017202719-A1 | NEW PHENYLPYRAZOLYLACETAMIDE COMPOUNDS AND DERIVATIVES AS CDK8/CDK19 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-11-30 | — | — | WO | disclosed |
| EP-1874303-A1 | PYRAZOLE COMPOUNDS AS PROSTAGLANDIN RECEPTORS LIGANDS | GLAXO GROUP LIMITED (GB) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006114313-A1 | PYRAZOLE COMPOUNDS AS PROSTAGLANDIN RECEPTORS LIGANDS | GLAXO GROUP LIMITED (GB) | 2006-11-02 | — | — | WO | disclosed |
| EP-1320531-A2 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | Pharmacia Italia S.p.A. (IT) | 2003-06-25 | — | — | EP | disclosed |
| WO-2002012242-A2 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PHARMACIA ITALIA S.P.A. (IT) | 2002-02-14 | — | — | WO | disclosed |
| CN-1022488-C | Antimuscainic bronchodilators | PFIZER (US) | 1993-10-20 | — | — | CN | disclosed |
| CN-1051041-A | Antimuscainic bronchodilators | PFIZER (US) | 1991-05-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11213520-B2 | Phenylpyrazolylacetamide compounds and derivatives as CDK8/CDK19 inhibitors | CDK9, CDK19, CDK8 | HTT 4320/4885GAA 3013/4885CTSD 3093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.